Department of Surgery, Division of Urology, Voiding Dysfunction Section, São Paulo Hospital-Federal University of São Paulo, São Paulo, Brazil.
Department of Surgery, Chief of Division of Urology and Voiding Dysfunction Section, São Paulo Hospital-Federal University of São Paulo, São Paulo, Brazil.
Prostate. 2023 Jun;83(9):857-862. doi: 10.1002/pros.24526. Epub 2023 Mar 21.
Male detrusor underactivity (DUA) definition remains controversial and no effective treatment is consolidated. Transurethral resection of the prostate (TURP) is one of the cornerstones surgical treatments recommended in bladder outlet obstruction (BOO). However, the role of prostatic surgery in male DUA is not clear. The primary endpoint was the clinical and voiding improvement based on IPSS and the maximum flow rate in uroflowmetry (Qmax) within 12 months.
We analyzed an ongoing prospective database that embraces benign prostata hyperplasia (BPH) male patients with lower urinary tract symptoms who have undergone to TURP. All patients were evaluated pre and postoperatively based on IPSS questionnaires, prostate volume measured by ultrasound, postvoid residual urine volume (PVR), Prostate Specific Antigen measurement and urodynamic study (UDS) before the procedure. After surgery, all patients were evaluated at 1-, 3-, 6- and 12-months. Patients were categorized in 3 groups: Group 1-Detrusor Underactive (Bladder Contractility Index (BCI) [BCI] < 100 and BOO index [BOOI] < 40); Group 2-Detrusor Underactive and BOO (BCI < 100 and BOOI ≥ 40); Group 3-BOO (BCI ≥ 100 and BOOI ≥ 0).
It was included 158 patients underwent monopolar or bipolar TURP since November 2015 to March 2021. According to UDS, patients were categorized in: group 1 (n = 39 patients); group 2 (n = 41 patients); group 3 (n = 77 patients). Preoperative IPSS was similar between groups (group 1-24.9 ± 6.33; group 2-24.8 ± 7.33; group 3-24.5 ± 6.23). Qmax was statistically lower in the group 2 (group 1-5.43 ± 3.69; group 2-3.91 ± 2.08; group 3-6.3 ± 3.18) as well as greater PVR. The 3 groups presented similar outcomes regard to IPSS score during the follow-up. There was a significant increase in Qmax in the 3 groups. However, group 1 presented the lowest Qmax improvement.
There were different objective outcomes depending on the degree of DUA at 12 months follow-up. Patients with DUA had similar IPSS improvement. However, DUA patients had worst Qmax improvement than men with normal bladder contraction.
男性逼尿肌活动低下(DUA)的定义仍然存在争议,没有有效的治疗方法得到巩固。经尿道前列腺切除术(TURP)是推荐用于膀胱出口梗阻(BOO)的基石手术治疗方法之一。然而,前列腺手术在男性 DUA 中的作用尚不清楚。主要终点是在 12 个月内基于国际前列腺症状评分(IPSS)和尿流率(Qmax)的最大流量进行临床和排尿改善。
我们分析了一个正在进行的前瞻性数据库,其中包括接受经尿道前列腺切除术(TURP)治疗的下尿路症状的良性前列腺增生(BPH)男性患者。所有患者均在术前根据 IPSS 问卷、超声测量的前列腺体积、残余尿量(PVR)、前列腺特异性抗原(PSA)测量和尿动力学研究(UDS)进行评估。手术后,所有患者在 1、3、6 和 12 个月时进行评估。患者分为 3 组:第 1 组-逼尿肌活动低下(膀胱收缩指数(BCI)[BCI]<100 和 BOO 指数[BOOI]<40);第 2 组-逼尿肌活动低下和 BOO(BCI<100 和 BOOI≥40);第 3 组-BOO(BCI≥100 和 BOOI≥0)。
纳入了 2015 年 11 月至 2021 年 3 月间接受单极或双极 TURP 的 158 例患者。根据 UDS,患者分为:第 1 组(n=39 例);第 2 组(n=41 例);第 3 组(n=77 例)。术前 IPSS 在组间相似(第 1 组-24.9±6.33;第 2 组-24.8±7.33;第 3 组-24.5±6.23)。第 2 组的 Qmax 统计学上较低(第 1 组-5.43±3.69;第 2 组-3.91±2.08;第 3 组-6.3±3.18),残余尿量也较大。在随访期间,3 组的 IPSS 评分均有相似的结果。3 组的 Qmax 均有显著增加。然而,第 1 组的 Qmax 改善最低。
在 12 个月的随访中,根据逼尿肌活动低下的程度有不同的客观结果。逼尿肌活动低下的患者的 IPSS 改善相似。然而,逼尿肌活动低下的患者的 Qmax 改善比正常膀胱收缩的男性差。